Kwality Pharmaceuticals Ltd Share Price Today - Kwality Pharmaceuticals Ltd Stock Price Live NSE/BSE

Kwality Pharmaceuticals Ltd

NSE: BSE: 539997

₹1710

(9.64%)

Fri, 13 Mar 2026, 03:13 am

MTF 5xInvest in Kwality Pharmaceuticals Ltd with 5x Leverage Buy with MTF

Market Cap16.18B

PE Ratio31.38

Dividend0

Health Technology

Pharmaceuticals: Major

24.5K

Kwality Pharmaceuticals Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

Market Cap
1725.46
Net Profit
39.80
P/B
3.43
Sector P/E
32.85
P/E
22.63
EV/EBITDA
12.14
Debt/Equity (Industry)
0.23
Interest Cover (Industry)
10.03
ROCE (Industry)
12.82
RONW (Industry)
12.23
ROE
16.36
ROCE
18.35
Debt/Equity
0.43
EPS (TTM)
55.06
Dividend Yield
0
Book Value
278.82
Interest Cover
6.48

Analysis

all

Pros

Kwality Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Kwality Pharmaceuticals is profitable, therefore cash runway is not a concern.
Kwality Pharmaceuticals is profitable, therefore cash runway is not a concern.
Debt is well covered by operating cash flow (63.2%, greater than 20% of total debt).
Debt is covered by short term assets, assets are 3.9x debt.

Cons

Unable to calculate sustainability of dividends as Kwality Pharmaceuticals has not reported any payouts.
Unable to evaluate Kwality Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Kwality Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
The level of debt compared to net worth has increased over the past 5 years (37.4% vs 53% today).
Kwality Pharmaceuticals's level of debt (53%) compared to net worth is high (greater than 40%).

Financials

Ratios

Shareholders	DEC 2025	SEPT 2025	JUN 2025	MAR 2025	DEC 2024
Promoters	54.83	54.83	54.83	54.83	54.83
FII	0.50	0	0	0	0
DII	0.33	0.33	0.33	0.32	0.03
Public	44.34	44.84	44.84	44.86	45.14
Government	0	0	0	0	0

Technical Analysis

RSI

70.00

MACD

103.21

50 DMA

1255.26

200 DMA

1060.43

Support and Resistance

Type	R3	R2	R1	PP	S1	S2	S3
Classic	2529.12	1962.42	1759.13	1395.72	1192.43	829.02	262.32
Fibonacci	1962.42	1745.94	1612.20	1395.72	1179.24	1045.50	829.02
Camarilla	1711.69	1659.74	1607.80	1395.72	1503.90	1451.95	1400.01

Pivots Level: Classic

+1133.40

2529.12

+566.70

1962.42

+363.42

1759.13

1395.72

Pivot Point

LTP: 1660.25

-203.28

1192.43

-566.70

829.02

-1133.40

262.32

Moving Average

SMAEMA

Period

Value

10-EMA
1539.41
20-EMA
1459.23
30-EMA
1394.65
50-EMA
1301.19
100-EMA
1177.34
200-EMA
1066.35

Announcement Date	Purpose	Action	Ex Date
12 Feb 2026	board-meetings	Quarterly Results
13 Nov 2025	board-meetings	Quarterly Results, Half Yearly Results
18 Aug 2025	agm
06 Sept 2024	agm
08 Sept 2023	agm
21 Sept 2022	agm
06 Sept 2021	agm
12 Sept 2017	bonus	Bonus issue 1:1	12 Oct 2017
22 Dec 2016	dividend	₹0.60 Dividend /Share	06 Jan 2017
06 Dec 2016	dividend	Interim Dividend - Rs. - 0.6	06 Jan 2017

Kwality Pharmaceuticals Ltd

Sun Pharmaceutical Industries Ltd

Torrent Pharmaceuticals Ltd

Dr Reddys Laboratories Ltd

Divis Laboratories Ltd

Lupin Ltd

Kwality Pharmaceuticals Ltd About

Kwality Pharmaceuticals operates as a pharmaceutical company. The Company manufactures and exports a broad range of finished pharmaceutical formulations in a dosage form. Kwality Pharmaceuticals markets its products in Asia and Africa.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1983

Headquarters

CEO

Employees

Contact

Website

http://www.kwalitypharma.com

cs@kwalitypharma.com

Phone

91-183-2774321-25

Location

Village Nagkalan, Majitha Road, Amritsar, Punjab, 143601

Year	History
2014	The Company received WHO certification.
2015	The name of the Company was changed to Kwality Pharmaceuticals Limited.
2016	Kwality Pharmaceuticals are listed and admitted to dealings on the Exchange in the list of 'MT' Group Securities. The Company's relevant documents were certified as not available/destroyed at the office of the RoC Chandigarh.
2017	The Company allotted 51,88,099 Equity Shares of Rs. 10/- each as Bonus Shares in the ratio of 1:1 to the shareholders.
2024	The Company received its first biological product permission for manufacturing and sale of Pegylated-Aspa.

Client Name	Order Side	QTY	Avg Price	Date
ARK GLOBAL EMERGING COMPANIES, LP	Buy	76400	1130.04	09 Jan 2026
DEEPAK BANSAL	Sell	69353	1122.42	09 Jan 2026
AKNM SUPPLIERS PRIVATE LIMITED	Sell	137152	316.41	10 Jul 2023
AKNM SUPPLIERS PRIVATE LIMITED	Sell	150000	295.1	03 Jul 2023
BLUEPEAK CONSULTANCY LLP	Buy	75000	295	03 Jul 2023
AKNM SUPPLIERS PRIVATE LIMITED	Sell	104000	295.38	30 Jun 2023
AKNM SUPPLIERS PRIVATE LIMITED	Sell	158564	294.07	26 Jun 2023
AKNM SUPPLIERS PRIVATE LIMITED	Sell	100000	295.49	08 Jun 2023
AKNM SUPPLIERS PRIVATE LIMITED	Sell	100000	295.19	05 Jun 2023
AKNM SUPPLIERS PRIVATE LIMITED	Sell	250000	344.24	19 Jan 2023

Kwality Pharmaceuticals Ltd News

Kwality Pharmaceuticals Seeks Shareholder Approval

Kwality Pharmaceuticals Limited issues postal ballot notice for appointment of two Independent Directors through remote e-voting from February 27 to March 28, 2026.

26 Feb 2026

stocks

Kwality Pharmaceuticals Q3 FY26 Results Show Strong Growth

Kwality Pharmaceuticals reported impressive Q3 FY26 results with revenue growing 46.2% YoY to INR 123.4 crore and PAT surging 87.8% to INR 16 crore, driven by expansion in regulated markets and capacity scaling.

12 Feb 2026

co actions results

Kwalite Pharma Board Meet on Feb 12 for Q3FY26 Results

Kwalite Pharmaceuticals Limited has scheduled its board meeting for February 12, 2026, to consider and approve Q3FY26 unaudited financial results. Trading window remains closed until 48 hours post-declaration.

02 Feb 2026

co actions results

Kwality Pharma Appoints Bhavesh Mahajan as Director

Kwality Pharmaceuticals Ltd appoints CA Bhavesh Mahajan as Additional Independent Director for 5-year term from January 28, 2026 to January 27, 2031, subject to shareholder approval.

28 Jan 2026

stocks

Kwality Pharma Appoints New Independent Director

Kwality Pharmaceuticals Limited has appointed Dr. PreetMohinder Singh Bedi as Additional Independent Director for a five-year term from January 1, 2026, to December 31, 2030.

01 Jan 2026

stocks

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800